Abstract:The recent coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2), has led to an unprecedented global health crisis that is still having profound impact on societies, economies and healthcare systems worldwide. Although SARS-CoV-2 is no longer the destructive pathogen it was at the beginning of the pandemic, the infection has now reached endemic proportions and continues to harm the most vulnerable segments of the population (i.e. elderly, immunocompromised individuals, patients with multiple comorbidities). Thus, irrespective of recent claims, the pandemic is not completely over, and we will need to find a "new normal" to live with this coronavirus by limiting the immediate impact of an acute infection on human health and the consequences that long-COVID (also known as "post-COVID" syndrome) may cause on the medium/long-term on health and fitness [1, 2]. It is precisely for this reason that the journal is still publishing some contributions on COVID-19, and will predictably continue to do so for the foreseeable future. Some of these articles are comprised in this issue of the journal. The first of these contributions, published by Lane et al. [3], describes a high-throughput peptide immunoaffinity liquid chromatography-mass spectrometry (SISCAPA-LC-MS) assay using polyclonal capture antibodies to detect and measure the nucleoprotein (N) of SARS-CoV-2 in human saliva. In the author's hands, the method exhibited acceptable specificity (i.e. 89.8 %), counterbalanced by a considerably poor sensitivity (i.e. 37.7 %), making its diagnostic performance even lower than that of some high-throughput SARS-CoV-2 antigen immunoassays currently available on the market [4]. In the second article, published by Ge et al. [5], a different approach for SARS-CoV-2 detection is presented, based on assessment of subgenomic RNA (sgRNA). The major advantage of this assay over standard molecular biology techniques that measure viral RNA is that sgRNA is only produced during virus replication and can hence be used as a valuable surrogate for individual infectivity. Therefore, notwithstanding the large heterogeneity of detection techniques, current evidence suggests that sgRNA could be used as a marker of viral replication, allowing the identification of individuals that are still spreading viable viruses, along with establishment of more appropriate treatments and/or isolation strategies. The following article by Schoenmakers et al. [6] examined the clinical significance of measuring a simple score called CoLab, based on age and ten laboratory tests (i.e., erythrocytes, leukocytes, eosinophilic granulocytes, basophilic granulocytes, bilirubin, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyltransferase, albumin and c-reactive protein) in patients with severe forms of COVID-19 who had to be admitted to the intensive care unit (ICU). The authors found a significant association between the CoLab score and viral load on admission and, more importantly, patient de-isolation could be predicted by CoLab, as a change in its score was significantly associated with gradual reduction in viral load. Since high viral load is a significant predictor of illness severity and unfavorable outcome in COVID-19 patients, the CoLab score could therefore be considered as a potential tool for prognostication and clinical management of patients with severe COVID-19 disease. In line with the previous article, Mink et al. [7] conducted a systematic literature review to decipher the potential prognostic value of anti-SARS-CoV-2 antibodies. The result of the literature search is remarkable, in that the authors included 33 studies with over 30 million individuals in their analysis. Overall, a highly significant association was found between anti-SARS-CoV-2 antibodies and lower risk of SARS-CoV-2 infection and better outcomes (including mortality). It was concluded that measurement of anti-SARS-CoV-2 antibodies may be a useful tool for timely identification of patients at higher risk of infection and/or clinical deterioration who may require booster vaccination or more aggressive therapeutic treatment. The search for reliable predictors of unfavorable clinical course of COVID-19 disease continues with the article published by Krčmová and colleagues [8]. In brief, the authors collected urine and blood for one week from 108 patients hospitalized with COVID-19 (55 vaccinated; 51 %), and used LC-MS/MS assays to measure neopterin, kynurenine, tryptophan, fat-soluble vitamins, and biomarkers of DNA damage. Overall, neopterin, kynurenine and the kynurenine/tryptophan ratio were found to decrease significantly between 4 and 7 days after hospitalization, but their concentration remained elevated in patients with unfavorable clinical course or post-COVID syndrome. In addition, significantly decreased levels of vitamins A, E and D were found in -Abstract Truncated-

LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Proteomic characteristics of the treatment trajectory of patients with COVID-19

Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges

Rapid Detection of COVID-19 Using MALDI-TOF-Based Serum Peptidome Profiling

Proteomic Profiling of COVID-19 Patients Sera: Differential Expression with Varying Disease Stage and Potential Biomarkers

Evaluation of serum and urine biomarkers for severe COVID-19

A Bioinformatics Approach to Mine the Microbial Proteomic Profile of COVID-19 Mass Spectrometry Data

Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise

Quantitative LC-MS study of compounds found predictive of COVID-19 severity and outcome

Development and translation of a method of clinical utility for LC-MS/MS analysis to detect SARS-CoV-2 antigens from ONP swabs and saliva

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Serum proteomics for the identification of biomarkers to flag predilection of COVID19 patients to various organ morbidities

Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis

The perspectives of biomarker-based electrochemical immunosensors, artificial intelligence and the Internet of Medical Things toward COVID-19 diagnosis and management

SARS-CoV-2 is here to stay: do not lower our guard

Clinical laboratory evaluation of COVID-19

Desorption Separation Ionization Mass Spectrometry (DSI-MS) for Rapid Analysis of COVID-19

Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19

Plasma Proteomics Elucidated a Protein Signature in COVID-19 Patients with Comorbidities and Early-Diagnosis Biomarkers